





Supplementary Figure S1. Genotyping diagrams of the *LEPR* gene rs1137101 variant using Sanger sequencing (A) and PCR-RFLP assay (B). PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.



Supplementary Figure S2. Flow diagram of the literature review process for this meta-analysis.

Supplementary Table S1. Main features of the included studies for this meta-analysis

References (Author, Year)	Year	Ethnicity	Country	Cancer Type ¹	Genotyping assay ²	Case, Control (n)			Correlation (Yes/No)
						Total	A/G	AA/AG/GG	
Domingos et al.	2014	Caucasian	Brazil	OC	PCR-RFLP	25, 89	31/19, 118/60	12/7/6, 40/38/11	Yes
Rodrigues et al.	2015	Caucasian	Brazil	OC	PCR-RFLP	129, 186	181/77, 228/144	60/61/8, 68/92/26	Yes
Hussain et al.	2015	Caucasian	India	OC	PCR-RFLP	306, 228	206/406, 96/360	48/110/148, 12/72/144	Yes
Hung et al.	2019	Asian	China	OC	TaqMan	567, 560	127/1007, 128/992	5/117/445, 10/108/442	No
Doecke et al.	2008	Caucasian	Australia	EC(EAC)	Sequenom	260, 1352	286/234, 1501/1203	73/140/47, 419/663/270	No
Doecke et al.	2008	Caucasian	Australia	EC(EGJAC)	Sequenom	301, 1352	322/280, 1501/1203	81/160/60, 419/663/270	No
Doecke et al.	2008	Caucasian	Australia	EC(ESCC)	Sequenom	213, 1352	234/192, 1501/1203	64/106/43, 419/663/270	No
Qiu et al.	2017	Asian	China	EC(ESCC)	SNPscan	504, 1489	120/888, 364/2614	6/108/390, 21/322/1146	Yes
Ren et al.	2010	Asian	China	GC	PCR-RFLP	117, 104	44/190, 22/186	3/38/76, 1/20/83	Yes
Pan et al.	2014	Asian	China	GC	PCR-RFLP	546, 632	142/950, 201/1063	11/120/415, 22/157/453	Yes
Ling et al.	2016	Asian	China	GC	PCR-RFLP	89, 97	19/159, 41/153	1/17/71, 6/29/62	Yes
This study_1	2023	Asian	China	GC	PCR-RFLP	460, 800	92/828, 211/1389	1/90/369, 13/185/602	No
Chia et al.	2007	Caucasian	America	CRC	MassARRAY	101, 100	NA, NA	AA/AG+GG=32/69, 33/67	No
Pechlivanis et al.	2009	Caucasian	Czech Republic	CRC	TaqMan	639, 706	678/600, 765/647	179/320/140, 202/361/143	No
Vašků et al.	2009	Caucasian	Czech Republic	CRC	PCR-RFLP	100, 100	102/98, 113/87	23/56/21, 34/45/21	No
Karimi et al.	2011	Asian	Iran	CRC	PCR-RFLP	173, 173	229/117, 214/132	77/75/21, 67/80/26	No
Mahmoudi et al.	2016	Asian	Iran	CRC	PCR-RFLP	261, 339	355/167, 439/239	127/101/33, 146/147/46	No
Lin et al.	2020	Asian	China	CRC	SNPscan	980, 1299	235/1725, 323/2275	15/205/760, 19/285/995	Yes
This study_2	2023	Asian	China	CRC	PCR-RFLP	787, 800	216/1358, 211/1389	12/192/583, 13/185/602	No
Li et al.	2012	Asian	China	LC	PCR-RFLP	417, 551	382/452, 634/468	87/208/122, 189/256/106	Yes
Zhang et al.	2018	Asian	China	LC	SNPscan	575, 920	125/1025, 213/1627	3/119/453, 10/193/717	No
Karam et al.	2020	Caucasian	Egypt	LC	PCR-RFLP	100, 50	45/155, 30/70	5/35/60, 5/20/25	Yes
Tang et al.	2020	Asian	China	LC	SNaPshot	149, 146	35/263, 35/257	2/31/116, 3/29/114	No
This study_3	2023	Asian	China	LC	PCR-RFLP	480, 800	87/873, 211/1389	3/81/396, 13/185/602	Yes

Note. ¹OC, oral cancer; EC, esophageal cancer; EAC, esophageal adenocarcinoma; EGJAC, esophagogastric junction adenocarcinoma; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; CRC, colorectal cancer; LC, liver cancer. ² PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.